Photorefractive Keratectomy (PRK) for Myopia Correction

Back

Background

Photorefractive keratectomy (PRK) consists of the application of energy of the ultraviolet range generated by an argon fluoride (ArF) excimer laser to the anterior corneal stroma to change its curvature and, thus, to correct a refractive error. The physical process of remodeling the corneal stroma by ultraviolet (193 nm wavelength) high-energy photons is known as photoablation.

An image depicting human eye anatomy can be seen below.



View Image

Human eye anatomy.

History of the Procedure

During the 1980s, several applications of the 193-nm ArF excimer laser were investigated, including its use on human corneas for the correction of refractive errors. In 1988, Munnerlyn, Kroons, and Marshall reported an algorithm relating diameter and depth of the ablation to the required dioptric change.

McDonald performed the first excimer PRK for the correction of myopia on a normally sighted human eye in the United States. That same year, the Food and Drug Administration (FDA) organized a phase 3 trial, the PRK study (which ended in 1996), to demonstrate the safety, predictability, and stability of PRK for the treatment of myopia. At the end of this trial, 2 ophthalmic companies, VISX and Summit, were allowed to manufacture excimer lasers for widespread use in the United States. Since then, Nidek also has obtained approval for the manufacture of excimer lasers in the United States, and several hundred thousand patients have undergone this procedure throughout the world. The first excimer lasers used to perform PRK in the late 1980s have been improved significantly in terms of size, efficiency, and accuracy.

Problem

Several epidemiological studies, including the Beaver Dam population-based survey taken in the United States, show a prevalence of myopia greater than 0.5 diopters (D), ranging from 43.0% in people aged 43-54 years to 14.4% in individuals older than 75 years.

Pathophysiology

The mechanism of ablation of the excimer laser appears to be photochemical in nature and is known as photochemical ablation or ablative photodecomposition. This highly localized tissue interaction is based on the fact that each photon produced by the ArF excimer laser has 6.4 eV of energy, enough to break covalent bonds.[1]

The intramolecular bonds of exposed organic macromolecules are broken when a large number of high-energy 193-nm photons are absorbed in a short time. The resulting fragments rapidly expand and are ejected from the exposed surface at supersonic velocities. This mechanism explains why only the irradiated organic materials are affected, whereas the adjacent areas are not affected.

The return of corneal innervation up to 5 years after PRK was measured. Corneal subbasal nerve density does not recover to near preoperative densities until 2 years after PRK, as compared to 5 years after laser in situ keratomileusis (LASIK).[2, 3]

A study comparing transepithelial PRK and laser surgery found that both offer effective correction of myopia at 1 year, but LASIK seemed to result in less discomfort and less intense wound healing in the early postoperative period.[4]

Indications

Clinical indications for PRK include the following:

Relevant Anatomy

PRK ablation of the anterior stroma takes place after removing the epithelium, which is approximately 40-50 µm in thickness. The Bowman layer is destroyed in the process of PRK with no known deleterious consequences. A residual stromal thickness of at least 250 µm after PRK is necessary to prevent future corneal ectasia. A residual stromal thickness of 400 µm or more is preferred. The epithelium can be removed via mechanical, laser, or chemical means.

Contraindications

Contraindications include collagen vascular, autoimmune, or immunodeficiency diseases; pregnancy or breastfeeding; keratoconus; medications, such as Accutane (isotretinoin) or Cordarone (amiodarone hydrochloride); and a history of keloid formation. A recent report on the outcome of PRK in African Americans, including those with a known history of dermatologic keloid formation, revealed that a history of keloid formation does not appear to have an adverse effect on the outcome. These results question whether known dermatologic keloid formation should be a contraindication to photorefractive keratectomy.

Other Tests

All patients who are surgical candidates for photorefractive keratectomy (PRK) should undergo preoperative screening with videokeratography (corneal topography) and corneal pachymetry. A high percentage of candidates for keratorefractive surgery have clinical or subclinical keratoconus. Preoperative corneal topography must be radially symmetric and free of irregular astigmatism; however, topographic-guided treatment of irregular astigmatism can be performed and is gaining in popularity. Patients suspected of having keratoconus are detected most easily with videokeratography using a 1.5-D interval scale by looking for a local area of corneal steepening.

Pseudokeratoconus is a form of localized corneal steepening caused by an artifact. The most common cause of pseudokeratoconus is found in contact lens wearers who have worn decentered contact lenses.

Contact lens warpage is a phenomenon resulting in destabilization of a patient's refraction. This effect may last for several weeks after contact lens use has been discontinued.

Quantitative descriptors of corneal optical performance, such as the Surface Regularity Index (SRI), can be helpful to quantify the smoothness of the ablation postoperatively.

Histologic Findings

The following histologic excimer-induced changes in corneal morphology have been reported:

Medical Therapy

Following photorefractive keratectomy (PRK), topical antibiotics should be used with a therapeutic contact lens until reepithelialization is complete. Furthermore, a weak corticosteroid, such as fluorometholone 0.1%, is frequently used to avoid excessive collagen deposition.

Topical intraoperative application of 0.02% mitomycin C can reduce haze formation in highly myopic eyes undergoing PRK.[6, 7, 8]

Preoperative Details

Preoperative evaluation before PRK includes the following:

Intraoperative Details

After placement of antibiotic and anesthetic drops in the eye, the eyelid is held open using a speculum. When using the mechanical epithelial removal technique, a 6.0- or 6.5-mm marker can be used, centered over the entrance pupil to mark the area where the epithelium is to be removed. The epithelium can be removed using a blunt spatula or a small blade, such as a Beaver 64.

After epithelial removal, the surface of the cornea must be wiped with a nonfragmenting sponge that has been soaked with balanced sterile saline and then squeezed so it is moist but not saturated. During the procedure, focusing properly on the stromal surface and avoiding excessive illumination to allow patient fixation are important. A Thornton ring or similar instrument can be used to gently help the patient maintain fixation without distorting the corneal surface.

The excimer laser beam is centered on the entrance pupil and focused on the anterior stromal surface, and the laser treatment is applied. Excimer lasers frequently have tracking devices to help properly center treatment.

Postoperative Details

Placing a therapeutic contact lens for an average of 3 days (and not uncommonly for up to 5 days) is helpful, and application of a combination of antibiotic/steroid drops is routine. Alternatively, a pressure patch following application of an antibiotic/steroid ointment is well tolerated. Analgesic and antianxiety oral medications can be used during the first 24 hours postoperatively.

Follow-up

Patients should be monitored daily after PRK until the reepithelialization is complete. At this time, the therapeutic contact lens can be removed, and the patient can be monitored 1 week later. The remaining follow-up interval times can double until the vision stabilizes.

For excellent patient education resources, visit eMedicineHealth's Eye and Vision Center. Also, see eMedicineHealth's patient education article Vision Correction Surgery.

Complications

Complications following PRK include the following:

Outcome and Prognosis

For predictability of outcome, investigators collected the following data from patients who were operated on with a VISX excimer laser in a prospective, nonrandomized, unmasked, multicenter PRK clinical study and followed them for at least 2 years:

Future and Controversies

Even though several reports demonstrate that long-term visual outcome of patients treated with PRK versus LASIK is equivalent for mild-to-moderate myopia, PRK has become a second choice procedure for most refractive surgeons.

When using the excimer laser, LASIK has become the preferred technique because of the lack of a significant amount of discomfort, the faster rate of postoperative visual rehabilitation, and the greater amount of stability.

However, PRK remains useful when treating patients whose corneas are too thin to perform LASIK and leaves a 250-µm stromal bed after the ablation is performed. PRK also is the procedure of choice when treating a refractive error associated with an uneven corneal surface or a superficial leukoma.

New tools for mapping the cornea, including wavefront technology, will provide more accurate information that can be linked to the excimer laser and allow a customized ablation.[9] However, one study found that wavefront-guided PRK offered no advantage over non – wavefront-guided PRK in predictability or safety.[10] Similarly, technical improvements in the design of excimer machines, such as eye-tracking devices, have minimized potential complications, such as decentration, following PRK.

Author

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Disclosure: Nothing to disclose.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Louis E Probst, MD, MD, Medical Director, TLC Laser Eye Centers

Disclosure: Nothing to disclose.

Chief Editor

Douglas R Lazzaro, MD, FAAO, FACS, Chairman, Professor of Ophthalmology, The Richard C Troutman, MD, Distinguished Chair in Ophthalmology and Ophthalmic Microsurgery, Department of Ophthalmology, State University of New York Downstate Medical Center; Chief of Ophthalmology, Director of Cornea, Director of Surgical Training, Kings County Hospital Center

Disclosure: Nothing to disclose.

Additional Contributors

Daniel S Durrie, MD, Director, Department of Ophthalmology, Division of Refractive Surgery, University of Kansas Medical Center

Disclosure: Received grant/research funds from Alcon Labs for independent contractor; Received grant/research funds from Abbott Medical Optics for independent contractor; Received ownership interest from Acufocus for consulting; Received ownership interest from WaveTec for consulting; Received grant/research funds from Topcon for independent contractor; Received grant/research funds from Avedro for independent contractor; Received grant/research funds from ReVitalVision for independent contractor.

References

  1. Guerin MB, Darcy F, O'Connor J, O'Keeffe M. Excimer laser photorefractive keratectomy for low to moderate myopia using a 5.0 mm treatment zone and no transitional zone: 16-year follow-up. J Cataract Refract Surg. 2012 Jul. 38(7):1246-50. [View Abstract]
  2. Manche EE, Haw WW. Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2011 Dec. 109:201-20. [View Abstract]
  3. Sia RK, Coe CD, Edwards JD, Ryan DS, Bower KS. Visual outcomes after Epi-LASIK and PRK for low and moderate myopia. J Refract Surg. 2012 Jan. 28(1):65-71. [View Abstract]
  4. Korkmaz S, Bilgihan K, Sul S, Hondur A. A Clinical and Confocal Microscopic Comparison of Transepithelial PRK and LASEK for Myopia. J Ophthalmol. 2014. 2014:784185. [View Abstract]
  5. Celik U, Bozkurt E, Celik B, Demirok A, Yilmaz OF. Pain, wound healing and refractive comparison of mechanical and transepithelial debridement in photorefractive keratectomy for myopia: Results of 1 year follow-up. Cont Lens Anterior Eye. 2014 Jul 28. [View Abstract]
  6. Shalaby A, Kaye GB, Gimbel HV. Mitomycin C in photorefractive keratectomy. J Refract Surg. 2009 Jan. 25(1 Suppl):S93-7. [View Abstract]
  7. Fazel F, Roshani L, Rezaei L. Two-step versus Single Application of Mitomycin-C in Photorefractive Keratectomy for High Myopia. J Ophthalmic Vis Res. 2012 Jan. 7(1):17-23. [View Abstract]
  8. Alevi D, Barsam A, Kruh J, Prince J, Perry HD, Donnenfeld ED. Photorefractive keratectomy with mitomycin-C for the combined treatment of myopia and subepithelial infiltrates after epidemic keratoconjunctivitis. J Cataract Refract Surg. 2012 Jun. 38(6):1028-33. [View Abstract]
  9. de Jong T, Wijdh RH, Koopmans SA, Jansonius NM. Describing the Corneal Shape after Wavefront-Optimized Photorefractive Keratectomy. Optom Vis Sci. 2014 Aug 28. [View Abstract]
  10. Kobashi H, Kamiya K, Hoshi K, Igarashi A, Shimizu K. Wavefront-Guided versus Non-Wavefront-Guided Photorefractive Keratectomy for Myopia: Meta-Analysis of Randomized Controlled Trials. PLoS One. 2014. 9(7):e103605. [View Abstract]
  11. Dausch D, Smecka Z, Klein R, et al. Excimer laser photorefractive keratectomy for hyperopia. J Cataract Refract Surg. 1997 Mar. 23(2):169-76. [View Abstract]
  12. Erie JC, McLaren JW, Hodge DO. Recovery of corneal subbasal nerve density after PRK and LASIK. Am J Ophthalmol. 2005 Dec. 140(6):1059-1064. [View Abstract]
  13. Gambato C, Ghirlando A, Moretto E. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology. 2005 Feb. 112(2):208-18; discussion 219. [View Abstract]
  14. Hashemi H, Miraftab M, Asgari S. Comparison of the visual outcomes between PRK-MMC and phakic IOL implantation in high myopic patients. Eye (Lond). 2014 Jul 4. [View Abstract]
  15. Krueger RR, Trokel SL. Quantitation of corneal ablation by ultraviolet laser light. Arch Ophthalmol. 1985 Nov. 103(11):1741-2. [View Abstract]
  16. McDonald MB, Kaufman HE, Frantz JM, et al. Excimer laser ablation in a human eye. Case report. Arch Ophthalmol. 1989 May. 107(5):641-2. [View Abstract]
  17. Munnerlyn CR, Koons SJ, Marshall J. Photorefractive keratectomy: a technique for laser refractive surgery. J Cataract Refract Surg. 1988 Jan. 14(1):46-52. [View Abstract]
  18. Nassiri N, Sheibani K, Safi S, Haghnegahdar M, Nassiri S, Panahi N, et al. Alcohol-Assisted Debridement in PRK with Intraoperative Mitomycin C. Optom Vis Sci. 2014 Sep. 91(9):1084-8. [View Abstract]
  19. O'Brart DP, Patsoura E, Jaycock P. Excimer laser photorefractive keratectomy for hyperopia: 7.5-year follow-up. J Cataract Refract Surg. 2005 Jun. 31(6):1104-13. [View Abstract]
  20. Paysse EA, Coats DK, Hussein MA. Long-term outcomes of photorefractive keratectomy for anisometropic amblyopia in children. Ophthalmology. 2006 Feb. 113(2):169-76. [View Abstract]
  21. Rajan MS, Jaycock P, O'Brart D. A long-term study of photorefractive keratectomy; 12-year follow-up. Ophthalmology. 2004 Oct. 111(10):1813-24. [View Abstract]
  22. Seiler T, Wollensak J. Myopic photorefractive keratectomy with the excimer laser. One-year follow-up. Ophthalmology. 1991 Aug. 98(8):1156-63. [View Abstract]
  23. Shaikh NM, Wee CE, Kaufman SC. The safety and efficacy of photorefractive keratectomy after laser in situ keratomileusis. J Refract Surg. 2005 Jul-Aug. 21(4):353-8. [View Abstract]
  24. Taboada J, Archibald CJ. An extreme sensitivity in the corneal epithelium to far UV ArF excimer laser pulses. Proceedings of the Aerospace Medical Association. San Antonio. 1981.
  25. Tanzer DJ, Isfahani A, Schallhorn SC. Photorefractive keratectomy in African Americans including those with known dermatologic keloid formation. Am J Ophthalmol. 1998 Nov. 126(5):625-9. [View Abstract]
  26. Taylor HR, Guest CS, Kelly P, Alpins NA. Comparison of excimer laser treatment of astigmatism and myopia. The Excimer Laser and Research Group. Arch Ophthalmol. 1993 Dec. 111(12):1621-6. [View Abstract]
  27. Uozato H, Guyton DL. Centering corneal surgical procedures. Am J Ophthalmol. 1987 Mar 15. 103(3 Pt 1):264-75. [View Abstract]
  28. Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 1994 Dec. 35(13):4344-7. [View Abstract]

Human eye anatomy.

Human eye anatomy.